Oncology represents one of MedTech’s most innovation-driven sectors, sitting at the intersection of diagnostics, therapeutics, imaging, and digital health. This innovation is driven by a significant global challenge: research published in The Lancet projects annual cancer cases could reach 30.5 million by 2050, with cancer-related deaths rising to 18.6 million. In parallel, the broader oncology market is projected to reach $776.3 billion by 2034, growing at a CAGR of 17.84%, reflecting sustained investment across cancer detection, treatment, and monitoring technologies.
The sector spans ablation technologies, radiotherapy and radiosurgery systems, brachytherapy, surgical oncology platforms, liquid biopsy technologies, companion diagnostics, and AI-enabled clinical solutions. Growth is being driven by rising cancer prevalence, the shift toward minimally invasive and organ-preserving interventions, and the increasing adoption of precision medicine across oncology workflows.
The integration of AI, particularly across tumour detection, radiomics, pathology, and treatment planning, is further reshaping the relationship between medical devices, diagnostics, and software. As oncology technologies become more complex, companies require leaders who combine clinical credibility with oncologists and radiologists, an understanding of evolving regulatory pathways, and the commercial expertise required to scale innovation in one of healthcare’s most heavily invested markets.